using the UKPDS risk engine. Statin adherence was measured as pill days covered (PDC) in the IADB.nl pharmacy research database. Cost-effectiveness was measured in costs per quality-adjusted life-year (QALY) form the health carepayers' perspective. Results: For an average patient aged 60 at diagnosis, statin treatment was highly cost-effective at around € 2,300 per QALY. Favourable costeffectiveness was robust in sensitivity analysis. Differences in age and 10-year cardiovascular risk showed large differences in cost-effectiveness from more than € 100,000 per QALY to almost being cost saving. For the average patient aged 40 at diabetes diagnosis, statin treatment for primary prevention was not cost-effective. ConClusions: Despite the non-adherence levels observed in actual practice, statin treatment is cost-effective for primary prevention in patients newly diagnosed with type 2 diabetes. Due to large differences in cost-effectiveness according to different risk and age groups, the efficiency of the treatment could be increased by targeting patients with relatively higher cardiovascular risk and higher ages. PCV84 DeVeloPment of noVel ImagIng tests to seleCt PatIents for InDIVIDualIzeD theraPIes: are they Worth further InVestment?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.